Niketa Patel

FDA investigator

Appears on 15 documents from 2016 to 2023, most often at sites in New Jersey. Most often cites production record review (21 CFR 211.192).

15
Documents on file
4.0
Observations per 483
2016
First seen
2023
Most recent

What they cite most

From 60 observations

Activity by year

2016: 2, 2017: 1, 2018: 6, 2019: 4, 2020: 1, 2023: 1

Where

New Jersey 6 · China 2 · India 2 · Japan 2 · Germany 1 · New York 1

Is Niketa Patel coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

15 documents, newest first
FirmOpen
483 Wuxi Fortune Pharmaceutical Co., Ltd.Sep 13, 2023 · Wuxi, China
483 Pfizer Manufacturing Deutschland GmbHFeb 7, 2020 · Freiburg im Breisgau, Germany
483 QUAGEN PHARMACEUTICALS LLCNov 8, 2019 · West Caldwell, New Jersey
483 International Trading Pharm Lab IncOct 29, 2019 · Paterson, New Jersey
483 Mandell's Clinical PharmacyJul 25, 2019 · Somerset, New Jersey
483 Unither Manufacturing LLCMay 22, 2019 · Rochester, New York
483 JO Cosmetics Co., Ltd.Oct 24, 2018 · Hanyu, Japan

About this profile

What does Niketa Patel inspect?

Niketa Patel appears on 15 documents on file covering 14 sites, most often in New Jersey.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.22 and 21 CFR 211.194(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Niketa Patel is dated Sep 13, 2023.